

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Year Ended December 31,	
	2019	2018
Grant and collaboration revenue	\$ 1,176	\$ 963
Operating expenses:		
Research and development	1,911	1,879
General and administrative	1,637	1,647
	3,548	3,526
Loss from operations	(2,372)	(2,563)
Other income (expense), net	2	3
	\$ (2,371)	\$ (2,560)
Net loss		
	\$ (39.25)	\$(15,310)
Net loss per common share		
Weighted average shares outstanding	60,402	164

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	December 31,	
	2019	2018
Assets:		
Cash and cash equivalents	\$ 283	\$ 260
Other current assets	164	360
Total current assets	447	620
Property and other assets	22	22
Total assets	\$ 469	\$ 642
Liabilities and stockholders' equity		
Total liabilities	\$ 2,043	\$ 1,664
Stockholders' equity (deficiency)	(1,574)	(1,022)
Total liabilities and stockholders' equity	\$ 469	\$ 642
Common Shares Outstanding	299,835	219